Miacalcic

Calcitonin salmon, the active ingredient in Miacalcic, is a calcitonin presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy in adult patients.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Miacalcic is a calcitonin analogue that acts on bone metabolism disorders and calcium dysregulation.

Osteoporosis: helps reduce bone turnover and supports maintenance of bone mineral density. Paget's disease of bone: normalises abnormal bone remodeling and reduces disease‑related pain. Hypercalcemia of malignancy: lowers elevated serum calcium levels by inhibiting bone resorption and enhancing renal calcium excretion.

Miacalcic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Flushing or warmth sensation - Headache or dizziness - Mild injection‑site pain or erythema

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Marked hypocalcemia with neuromuscular symptoms - Hypotension or syncope - Severe injection‑site infection or abscess

Before initiating therapy, clinicians should evaluate calcium status and renal function.

Assess calcium levels before use: ensure baseline serum calcium is within normal range. Monitor for signs of hypocalcemia: watch for tingling, muscle cramps, or seizures. Use with caution in renal impairment: adjust monitoring frequency. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcitonin may interact with several agents that affect calcium balance or renal function.

Major Interactions (Avoid): - Calcium supplements: may diminish calcitonin efficacy. - NSAIDs: increase risk of renal impairment. - Loop diuretics: alter calcium handling and may exacerbate hypocalcemia. - Warfarin: potential for increased bleeding risk.

Moderate Interactions (Monitor Closely): - Bisphosphonates: additive inhibition of bone resorption. - Systemic steroids: may affect calcium metabolism. - Anticonvulsants (e.g., phenytoin): can modify calcium levels.